Back to search results

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Autoimmune Disorders · Systemic Sclerosis · Systemic Lupus Erythematosus · Lupus · Lupus Nephritis

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Chitra Chitra, MD) · cmhosing@mdanderson.org · 713-745-3219
    Contact: Principal Investigator (Chitra Hosing, MD)

  • The University of Texas Health Science Center at Houston, Houston, Texas, United States

    Contact: Study coordinator (Shervin Assassi, MD) · shervin.assassi@uth.tmc.edu · 713-500-7118
    Contact: Principal Investigator (Shervin Assassi, MD)
Study leads

  • Chitra Hosing, MD

    Principal Investigator

    MDAnderson Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)